tradmap

JSPR Earnings Jasper Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$10 -$5 $0 2021 2022 2023 2024 2025
EPS
Net income (annual)
-$71M -$36M $0 2020 2021 2022 2023 2024 2025
Net income
Return on equity (annual)
-116% -13% 90% 0% 2020 2021 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$5 -$2 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$27M -$13M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-219% -110% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–20 of 20
Q2 20262026-06-30-0.142026-08-1410-Q
Q1 20262026-03-31-0.042026-05-1410-Q
FY 20252025-12-31-3.952026-03-3010-K
Q3 20252025-09-30-4.182025-11-1010-Q
Q2 20262025-06-30-3.162026-08-1410-Q
Q1 20262025-03-31-1.412026-05-1410-Q
FY 20252024-12-31-4.892026-03-3010-K
Q3 20252024-09-30-3.252025-11-1010-Q
Q2 20252024-06-30-2.002025-08-1310-Q
Q1 20252024-03-31-1.032025-05-1210-Q
FY 20242023-12-31-6.182025-02-2810-K
Q3 20242023-09-30-4.682024-11-0710-Q
Q2 20242023-06-30-3.082024-08-1310-Q
Q1 20242023-03-31-1.622024-05-1410-Q
FY 20232022-12-31-10.332024-03-0510-K
Q3 20232022-09-30-0.672023-11-0910-Q
Q2 20232022-06-30-0.352023-08-1110-Q
Q1 20232022-03-31-0.062023-05-1210-Q
FY 20222021-12-31-2.692023-03-0810-K
Q3 20222021-09-30-7.132022-11-1010-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.